Neuroscience

Investigational drug may reduce involuntary movements

Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will ...

Oncology & Cancer

New trial drug a 'Trojan Horse' attacking pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare ...

Diseases, Conditions, Syndromes

Promising new antibiotic targets potentially deadly gut infections

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have developed a promising new antibiotic to treat potentially deadly gastrointestinal infections without harming the beneficial probiotic bacteria ...

Oncology & Cancer

A new method for prostate cancer imaging

Prostate cancer is one of the most common cancers in men. Tumor growth is critically regulated by the androgen receptor, and treatment strategies to lower androgens, such as testosterone, are a mainstay of clinical treatment. ...

page 3 from 12